BMY.N Relative Valuation
BMY.N's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BMY.N is overvalued; if below, it's undervalued.
Historical Valuation
Bristol-Myers Squibb Co (BMY.N) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of 11.31. The fair price of Bristol-Myers Squibb Co (BMY.N) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 51.95 USD , Bristol-Myers Squibb Co is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：51.95
Fair
Undervalued
8.34
PE
1Y
3Y
5Y
Trailing
Forward
8.65
EV/EBITDA
Bristol-Myers Squibb Co. (BMY.N) has a current EV/EBITDA of 8.65. The 5-year average EV/EBITDA is 10.00. The thresholds are as follows: Strongly Undervalued below 1.52, Undervalued between 1.52 and 5.76, Fairly Valued between 14.24 and 5.76, Overvalued between 14.24 and 18.48, and Strongly Overvalued above 18.48. The current Forward EV/EBITDA of 8.65 falls within the Historic Trend Line -Fairly Valued range.
8.52
EV/EBIT
Bristol-Myers Squibb Co. (BMY.N) has a current EV/EBIT of 8.52. The 5-year average EV/EBIT is 10.00. The thresholds are as follows: Strongly Undervalued below 0.68, Undervalued between 0.68 and 5.34, Fairly Valued between 14.67 and 5.34, Overvalued between 14.67 and 19.33, and Strongly Overvalued above 19.33. The current Forward EV/EBIT of 8.52 falls within the Historic Trend Line -Fairly Valued range.
2.28
PS
Bristol-Myers Squibb Co. (BMY.N) has a current PS of 2.28. The 5-year average PS is 2.75. The thresholds are as follows: Strongly Undervalued below 1.69, Undervalued between 1.69 and 2.22, Fairly Valued between 3.28 and 2.22, Overvalued between 3.28 and 3.82, and Strongly Overvalued above 3.82. The current Forward PS of 2.28 falls within the Historic Trend Line -Fairly Valued range.
9.48
P/OCF
Bristol-Myers Squibb Co. (BMY.N) has a current P/OCF of 9.48. The 5-year average P/OCF is 8.30. The thresholds are as follows: Strongly Undervalued below 6.36, Undervalued between 6.36 and 7.33, Fairly Valued between 9.27 and 7.33, Overvalued between 9.27 and 10.24, and Strongly Overvalued above 10.24. The current Forward P/OCF of 9.48 falls within the Overvalued range.
7.30
P/FCF
Bristol-Myers Squibb Co. (BMY.N) has a current P/FCF of 7.30. The 5-year average P/FCF is 7.84. The thresholds are as follows: Strongly Undervalued below 5.48, Undervalued between 5.48 and 6.66, Fairly Valued between 9.02 and 6.66, Overvalued between 9.02 and 10.20, and Strongly Overvalued above 10.20. The current Forward P/FCF of 7.30 falls within the Historic Trend Line -Fairly Valued range.
Bristol-Myers Squibb Co (BMY.N) has a current Price-to-Book (P/B) ratio of 5.70. Compared to its 3-year average P/B ratio of 5.11 , the current P/B ratio is approximately 11.61% higher. Relative to its 5-year average P/B ratio of 4.73, the current P/B ratio is about 20.65% higher. Bristol-Myers Squibb Co (BMY.N) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 11.66%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 10.73% , the current FCF yield is about -100.00% lower.
5.70
P/B
Median3y
5.11
Median5y
4.73
14.75
FCF Yield
Median3y
11.66
Median5y
10.73
Competitors Valuation Multiple
The average P/S ratio for BMY.N's competitors is 3.03, providing a benchmark for relative valuation. Bristol-Myers Squibb Co Corp (BMY.N) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BMY.N decreased by 6.13% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 10.22 to 17.96.
The secondary factor is the Revenue Growth, contributed 2.77%to the performance.
Overall, the performance of BMY.N in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Bristol-Myers Squibb Co (BMY.N) currently overvalued or undervalued?
What is Bristol-Myers Squibb Co (BMY.N) fair value?
How does BMY.N's valuation metrics compare to the industry average?
What is the current P/B ratio for Bristol-Myers Squibb Co (BMY.N) as of Dec 05 2025?
What is the current FCF Yield for Bristol-Myers Squibb Co (BMY.N) as of Dec 05 2025?
What is the current Forward P/E ratio for Bristol-Myers Squibb Co (BMY.N) as of Dec 05 2025?